AbCellera Biologics Inc Dossier - Source-backed chat

AbCellera Biologics Inc

ABCLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.13

Intrinsic Value $5.12median of 2 methodsbased on filings through 30 Jun 2026

Market Price $14.59Price as of 30 Sep 2026

Significantly overvaluedIntrinsic value is 65% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-65%)

Data confidence Sign in to view data confidence

Market Cap $4.7B

Enterprise Value $4.6B

Shares Outstanding 304.9M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AbCellera Biologics is successfully transitioning from a partnership-driven antibody discovery platform to a clinical-stage biopharmaceutical company with a proprietary internal pipeline. The company's investment thesis is anchored by its lead asset, ABCL635, a potential first-in-class once-monthly subcutaneous antibody targeting the NK3 receptor for non-hormonal treatment of menopausal vasomotor symptoms (VMS). Positive interim Phase 1 data has validated the platform's ability to target complex GPCRs, and the upcoming Phase 2 readout in Q3 2026 represents a major near-term catalyst. Backed by a robust liquidity position of approximately $655 million, AbCellera has a multi-year cash runway to fund its clinical programs well beyond the next three years, mitigating near-term financing risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$17.13

High · most bullish analyst$30.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0020%

ABCL635 Phase 2 trial fails to show sufficient efficacy or reveals unexpected safety concerns, invalidating the lead program and severely damaging the credibility of the internal pipeline strategy. The stock experiences a sharp sell-off, and the company is forced to rely on its remaining cash balance and slower-progressing partner-led programs, leading to a prolonged period of depressed valuation.

Base CaseCentral scenario

$17.1350%

Matches the consensus mean

ABCL635 Phase 2 trial meets its primary endpoints in Q3 2026, showing clear efficacy in reducing VMS frequency and severity with a favorable safety profile. The company proceeds with late-stage development planning for 2027. ABCL575 advances steadily through Phase 1, and the company maintains its disciplined cash burn, ending 2026 with strong liquidity. The market recognizes the value of the internal pipeline, driving the stock toward the consensus analyst target.

Bull CaseUpside scenario

$30.0030%

ABCL635 Phase 2 trial delivers strong efficacy and safety data in Q3 2026, demonstrating competitive advantages over small-molecule NK3R antagonists (such as once-monthly dosing and no liver toxicity). This triggers a major upward re-rating of the stock, validates the GPCR platform, and positions AbCellera to capture a significant share of the multi-billion-dollar non-hormonal VMS market. Additionally, ABCL575 delivers positive Phase 1 data in Q4 2026, and partner-led programs continue to advance, generating milestone revenues.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong liquidity position of approximately $655 million provides a multi-year cash runway to fund clinical development without near-term dilution.
ABCL635 represents a potential first-in-class, once-monthly non-hormonal treatment for a multi-billion-dollar VMS market with positive interim Phase 1 validation.
Successful transition to a clinical-stage biotech company with a fully built antibody discovery and clinical manufacturing platform.

Key Investment Risks

High clinical and scientific risk associated with translating biomarker target engagement into clinical efficacy in Phase 2/3 trials.
Elevated R&D expenses and ongoing net losses as the company shifts resources to its internal pipeline.
Potential volatility and binary outcomes tied to upcoming clinical readouts.

Thesis Invalidation Triggers

Failure of ABCL635 to meet efficacy or safety endpoints in the Phase 2 clinical trial in Q3 2026.
Significant delays in IND-enabling activities for pipeline candidates ABCL688 and ABCL386.
Rapid and unmanaged acceleration of cash burn that shortens the projected runway to under two years.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.